Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBMT 2020 | HSCT for AML patients with FLT3-ITD: clinical practice recommendations

Ali Bazarbachi • 18 Aug 2020
EBMT 2020
Acute Myeloid Leukemia Leukemia Sorafenib

Ali Bazarbachi, MD, PhD, American University of Beirut Medical Center, Beirut, Lebanon, discusses clinical practice recommendations in hematopoietic stem cell transplant (HSCT) for acute myeloid leukemia (AML) patients with FLT3-internal tandem duplications (FLT3-ITD). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Ali Bazarbachi

6:52
Somatic mutations that impact alloSCT outcomes in patients with AML
Ali Bazarbachi • 19 Dec 2023
8:11
Improvements over time in elderly patients with AML treated with alloSCT: an EBMT Registry study
Ali Bazarbachi • 19 Dec 2023
11:16
Latest advancements in alloHSCT for ALL
Ali Bazarbachi • 21 Mar 2022
9:06
Advances in the management of R/R Hodgkin lymphoma
Ali Bazarbachi • 28 Sep 2021

Related Videos

2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals